Shots: Ginkgo is eligible to receive up front, R& D fees including milestones in the form of Selecta common stock, clinical & commercial milestones of ~$85M in cash along with […]readmore
Tags : Rare Diseases
Shots: Alnylam to add an additional investigational product through the end of IND-enabling studies in Sanofi’s subsidiary Genzyme and Alnylam in 2014 deal, where companies collaborated to develop and commercialize […]readmore